TIM3-mediated differentiation of IL-10-producing CD25⁺ B cells by expanded regulatory T cells.

ABSTRACT: Cell-based immunotherapy utilizing regulatory T cells (Tregs) has recently advanced into clinical applications, demonstrating promising results in phase I/II trials to prevent transplant rejection and treat autoimmune diseases. We have completed a clinical trial in renal transplant patients in which the significant biological effect was the increase of B cells with a regulatory phenotype in the blood of kidney transplant patients. The mechanisms by which Tregs regulate B cells and the specific molecules involved in this process remained poorly understood. In this study, we employed an in vitro system of co-culture of peripherally purified B cells and expanded Tregs to show that Tregs can induce a population of memory B cells that express IL-10 and CD25. This subset of B cells has been prev

SUBMITTER: Alhabbab RY 

PROVIDER: S-EPMC12743028 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature